AI Earnings Predictions for Phibro Animal Health Corporation (PAHC)

EX-99.1

2 pahc-20260826xex99d1.htm

EX-99.1

​

Exhibit 99.1

​

For Immediate Release

​

Phibro Animal Health Corporation Reports Fourth Quarter and Fiscal Year Results, Provides Financial Guidance

​

TEANECK, N.J., August 26, 2026 (Business Wire) – Phibro Animal Health Corporation (Nasdaq: PAHC) (“Phibro” or the “Company”) today announced financial results for its fourth quarter and fiscal year ended June 30, 2026 and provided its financial guidance for the fiscal year ending June 30, 2027.

​

Highlights for the three months ended June 30, 2026 (compared to the three months ended June 30, 2025)

​

-Net sales of $396.7 million, an increase of $18.1 million, or 5%

-Net income of $21.7 million, an increase of $4.5 million, or 26%

-Diluted earnings per share of $0.53, an increase of $0.11, or 26%

-Adjusted EBITDA of $64.2 million, an increase of $14.3 million, or 29%

-Adjusted net income of $35.0 million, an increase of $9.4 million, or 37%

-Adjusted diluted EPS of $0.85, an increase of $0.22, or 35%

Highlights for the year ended June 30, 2026 (compared to the year ended June 30, 2025)

​

–Net sales of $1,518.1 million, an increase of $221.9 million, or 17%

–Net income of $99.7 million, an increase of $51.5 million

–Diluted earnings per share of $2.43, an increase of $1.24

–Adjusted EBITDA of $255.0 million, an increase of $71.3 million, or 39%

-Adjusted net income of $131.7 million, an increase of $43.6 million, or 49%

-Adjusted diluted EPS of $3.22, an increase of $1.05, or 48%

We are providing full fiscal year 2027 guidance, which includes:

​

-Net sales of $1.55 billion to $1.60 billion

-Adjusted EBITDA of $258 million to $268 million

-Adjusted net income of $140 million to $147 million

​

MFA SITE CLOSURE

​

Through the MFA acquisition in 2024, Phibro added several manufacturing facilities. Since then, we have conducted a comprehensive review of our manufacturing network to ensure our production footprint is aligned with current business needs and future operational requirements. As a result, we have decided to close our Chicago Heights manufacturing facility as part of a strategic consolidation of our manufacturing network. Production at the site is expected to cease during the summer of 2027. Approximately 100 employees will be affected. Manufacturing of products currently produced at Chicago Heights will be transferred to other Phibro-owned facilities and select third-party contract manufacturers.

​

​

1

​

COMMENTARY

​

“Fiscal 2026 was a year of meaningful progress for Phibro,” said Dani Bendheim, President and Chief Executive Officer of Phibro Animal Health Corporation. “We delivered record net sales of $1.5 billion, increased Adjusted EBITDA by 39% to $255 million, expanded margins, and continued to improve our business. These results reflect the dedication of our employees around the world and the value of our diversified portfolio.” ​

“As I begin my tenure as Chief Executive Officer, I am focused on building on that progress while positioning the Company for long-term success.”

“June 30, 2026 marked the formal conclusion of Phibro Forward, our enterprise-wide transformation program. Over the past three years, the program improved accountability, sharpened execution, and strengthened the way we operate. The benefits are already reflected in our performance today. Based on our fiscal 2027 outlook, nearly one out of every five dollars of Adjusted EBITDA can be traced to Phibro Forward initiatives realized since the start of the program. Just as importantly, the capabilities and culture established through the program remain embedded throughout the organization and will continue to drive performance going forward.”

“Today, we are announcing the planned closure of our Chicago Heights manufacturing facility following a comprehensive review of our manufacturing network after the MFA acquisition. This is a strategic network decision and not a reflection of the commitment, performance, or dedication of the people who work at Chicago Heights. Their dedication and contributions are what made this such a difficult decision. However, we believe it is the right long-term decision to better align our manufacturing footprint with future needs, improve efficiency, and strengthen our competitiveness. As one would expect from Phibro, we are committed to approaching this transition with honesty, transparency, and support for our employees.”

“Looking ahead to fiscal 2027, we expect continued growth across our businesses. Our guidance reflects a prudent view of known uncertainties, most notably the regulatory status of virginiamycin in Brazil. While we remain confident that we will ultimately obtain the required therapeutic indications and there remains a possibility that approval could occur before the current phase-out period expires in a little over a month, we have assumed only minimal virginiamycin sales in Brazil in our outlook. As a result, a favorable regulatory outcome would repr

EX-99.1

2 pahc-20260506xex99d1.htm

EX-99.1

​

Exhibit 99.1

​

​

​

​

For Immediate Release

​

Phibro Animal Health Corporation Reports Third Quarter Results, Updates Financial Guidance

​

TEANECK, N.J., May 6, 2026 (Business Wire) – Phibro Animal Health Corporation (Nasdaq: PAHC) (“Phibro” or the “Company”) today announced financial results for its third quarter ended March 31, 2026, and its updated financial guidance for the year ending June 30, 2026.

​

Highlights for the three months ended March 31, 2026 (compared to the three months ended March 31, 2025):

​

-Net sales of $383.5 million, an increase of $35.7 million, or 10%

-Net income of $24.0 million, an increase of $3.1 million, or 15%

-Diluted earnings per share of $0.59, an increase of $0.08, or 16%

-Adjusted EBITDA of $60.8 million, an increase of $5.9 million, or 11%

-Adjusted net income of $31.2 million, an increase of $5.0 million, or 19%

-Adjusted diluted EPS of $0.76, an increase of $0.12, or 19%

​

We have updated our fiscal year 2026 guidance, which includes:

​

-Net sales of $1.46 billion to $1.50 billion

-Adjusted EBITDA of $247 million to $255 million

​

COMMENTARY

​

“Phibro delivered a strong third quarter, with net sales increasing 10% to $383.5 million and adjusted EBITDA rising 11% to $60.8 million,” said Jack Bendheim, Chairman, President and Chief Executive Officer of Phibro Animal Health Corporation. “Results were driven by continued strength in our Animal Health business, where sales increased 13%, supported by robust demand across MFAs, nutritional specialties, and vaccines.”

​

“After quarter end, we announced a regulatory development in Brazil affecting certain antimicrobial products. In the past week, we also increased the size of our revolving credit facility by $125 million through an oversubscribed process, further strengthening our liquidity and financial flexibility. And finally yesterday, we announced the launch of our Sustainable Solutions Platform, including the introduction of VERRATAIN™ Verified Sustainability Solutions.”

​

“Based on our performance to date and improved visibility into the remainder of the fiscal year, we updated our full year guidance by increasing the lower end of several of our guidance ranges, resulting in higher midpoints across key financial measures.”

​

​

​

1

​

QUARTERLY RESULTS

​

Net sales

​

Net sales of $383.5 million for the three months ended March 31, 2026 increased $35.7 million, or 10%, as compared to the three months ended March 31, 2025. Animal Health increased $32.8 million, Mineral Nutrition increased $6.6 million, and Performance Products decreased $3.8 million.

Animal Health

Net sales of $291.2 million for the three months ended March 31, 2026 increased $32.8 million, or 13%. Net sales of MFAs and other increased $24.1 million, or 13%, due to an $18.9 million increase in the sales of products from the MFA portfolio acquired on October 31, 2024, increased demand for certain of our legacy MFAs in North America and for certain anti-microbials sold by our ethanol performance business.

Net sales of nutritional specialty products increased $3.5 million, or 8%, primarily due to increased demand in North America and higher companion animal sales.

Net sales of vaccines increased $5.2 million, or 16%, primarily due to an increase in international sales driven by higher demand in Israel, as well as an increase in domestic swine demand and higher sales of autogenous vaccines.

Mineral Nutrition

Net sales of $73.4 million for the three months ended March 31, 2026 increased $6.6 million, or 10%, due to an increase in demand for zinc and trace minerals.

Performance Products

Net sales of $18.9 million for the three months ended March 31, 2026 decreased $3.8 million, or 17%, as a result of lower demand for the ingredients used in personal care products.

Gross profit

Gross profit of $125.7 million for the three months ended March 31, 2026 increased $21.1 million, or 20%, as compared to the three months ended March 31, 2025. Gross margin increased 270 basis points to 32.8% of net sales for the three months ended March 31, 2026, as compared to 30.1% for the three months ended March 31, 2025. The comparison of gross profit to the prior year includes $3.8 million of prior period inventory write-offs attributable to the closure of an immaterial business, $1.7 million for prior period acquisition-related cost of goods sold related to the purchase accounting for the Acquisition, and a net increase in acquisition-related depreciation expense associated with the step-up of fair value of the acquired fixed assets and intangible asset amortization of $1.1 million. Excluding these items, gross profit increased $16.7 million, or 15%, and gross margin increased 130 basis points to 33.5% of net sales due to increased sales volume, favorable product mix, and increases in average selling prices, partially offset by higher input and distribution costs.

Animal Health gross p

Phibro Animal Health Corporation_February 4, 2026 0001069899false00010698992026-02-042026-02-04 ​ ​

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

​

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(D) OF THE

SECURITIES EXCHANGE ACT OF 1934

Date of report (Date of earliest event reported): February 4, 2026 Phibro Animal Health Corporation

(EXACT NAME OF REGISTRANT AS SPECIFIED IN CHARTER)

​

Delaware ​ ​ ​ 001-36410 ​ ​ ​ 13-1840497

(State or other jurisdiction of incorporation)

(Commission File Number)

(IRS Employer Identification No.)

​ Glenpointe Centre East, 3rd Floor 300 Frank W. Burr Boulevard, Suite 21 Teaneck, New Jersey 07666-6712 (Address of Principal Executive Offices, including Zip Code) ​ (201) 329-7300 (Registrant’s telephone number, including area code) Not Applicable (Former name or former address, if changed since last report) Securities registered pursuant to Section 12(b) of the Act: ​ Title of each class ​ ​ ​ Trading Symbol(s) ​ ​ ​ Name of each exchange on which registered

Class A Common Stock, $0.0001 par value per share ​

PAHC

​ NASDAQ Stock Market

​ Check the appropriate box below if this Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐ ​ ​

ITEM 2.02     RESULTS OF OPERATIONS AND FINANCIAL CONDITION.

On February 4, 2026, Phibro Animal Health Corporation issued a press release announcing its operating results for the fiscal quarter ended December 31, 2025 and its financial guidance for the fiscal year ending June 30, 2026. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information contained in this report, including the exhibit attached hereto, is being furnished and shall not be deemed to be “filed” for purposes of Section 18 of, or otherwise regarded as filed under, the Securities Exchange Act of 1934, as amended (the “Exchange Act”), nor shall it be deemed incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

ITEM 9.01     FINANCIAL STATEMENTS AND EXHIBITS.

(d) Exhibits Exhibit Number ​ ​ ​ Description

99.1

Press Release, dated February 4, 2026

​ ​ ​

104 ​ Cover Page Interactive Data File (embedded within the Inline XBRL document).

​ ​ ​

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. ​

PHIBRO ANIMAL HEALTH CORPORATION

Registrant

​ ​

Date: February 4, 2026 ​

​ ​

​ By: /s/ Judith Weinstein

​ Name: Judith Weinstein

​ Title: Senior Vice President, General Counsel and Corporate Secretary

​ ​ ​